Annual Report from Cyxone AB for the period 1 January 2020 to 31 December 2020
Cyxone AB’s Annual Report for the financial year 2020 is now available at the company’s website (www.cyxone.com).Please see attached Annual Report as pdf. Contact Tara Heitner, CEOTel: +46 70 781 88 08Email: tara.heitner@cyxone.comAdelgatan 21211 22 Malmö, Sweden About Cyxone Cyxone AB (publ) (Nasdaq First North Growth Market: CYXO) develops disease modifying therapies for diseases such as rheumatoid arthritis and multiple sclerosis as well as treatments for virally induced acute respiratory disorders. Rabeximod is a Phase 2 candidate drug being evaluated for the